journal article·2022-10-14Open access

H2O2-Responsive Nanocarriers Prepared by RAFT-Mediated Polymerization-Induced Self-Assembly of N-(2-(Methylthio)ethyl)acrylamide for Biomedical Applications

Hien Phan, Robert Cavanagh, Damien Destouches, Francis Vacherot, Blandine Brissault, Vincenzo Taresco, Jacques Penelle, Benoit Couturaud

ACS Applied Polymer Materials· Volume 4· Issue 10

Abstract

H2O2-sensitive block copolymer nanoparticles (NPs) composed of a hydrophilic macro-chain transfer agent (macro-CTA) and a hydrophobic thioether-bearing block were prepared by polymerization-induced self-assembly (PISA) approach. The PISA process first involved the chain extension of poly((poly(ethylene glycol) methyl ether methacrylate)-co-(poly(ethylene glycol) methacrylate)) macro-CTA with a H2O2-responsive N-(2-(methylthio)ethyl)acrylamide (MTEAM) monomer, which self-assembled into P((PEGMA-co-PEGMAOH)-b-PMTEAM) block copolymer NPs. The polymerization kinetics indicated the evolution of particle size and morphology from spherical micelles, fused micelles, to vesicles over time. Upon incubation with 0.1 to 10 mM H2O2, spheres were fragmented due to the oxidation of the PMTEAM cores, thus transforming the hydrophobic thioethers into hydrophilic sulfoxides and disassociating the nanocarriers. 43% of the hydrophobic Nile red dye was encapsulated into the spherical micelles and demonstrated a controlled release in H2O2 incubation. Spherical micelles and vesicles displayed no cytotoxicity in MCF-7, DU145, and 22Rv1 cells. Both spheres and vesicles were efficiently internalized into MCF-7 cells, with spheres showing a higher level of uptake than vesicles due to the smaller sizes. In summary, PISA of P((PEGMA-co-PEGMAOH)-b-PMTEAM) allowed the direct formation and loading of hydrophobic dye into spherical micelles, which showed a controlled drug release in H2O2.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Polymer Synthesis and Characterization · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institut de Chimie et des Matériaux Paris-Est, Université de Paris-Est Créteil, CNRS UMR 7182, 2 rue Henri Dunant, 94320 Thiais, France

School of Medicine, University of Nottingham, University Park, Nottingham NG7 2RD, U.K.

Univ Paris Est Créteil, TRePCa, F-94010 Créteil, France

School of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, U.K.

Funding

Universit? Paris-Est Cr?teil Val-de-Marne · DIM Respore

References (77)

Show source-provided references
1. 10.1016/j.addr.2012.09.02610.1016/j.addr.2012.09.026 ↗
2. 10.1002/jps.1039710.1002/jps.10397 ↗
3. 10.1002/adtp.20200010310.1002/adtp.202000103 ↗
4. 10.1039/C9BM00667B10.1039/C9BM00667B ↗
5. 10.1002/pola.2945110.1002/pola.29451 ↗
6. 10.1016/j.progpolymsci.2010.06.00310.1016/j.progpolymsci.2010.06.003 ↗
7. 10.1039/D0BM01406K10.1039/D0BM01406K ↗
8. 10.1021/acs.macromol.5b0260210.1021/acs.macromol.5b02602 ↗
9. Lansalot M. · Macromol. Rapid Commun. · 2019 · 40 · 110.1002/marc.201800885 ↗
10. 10.1002/anie.20180961410.1002/anie.201809614 ↗
11. 10.1002/marc.20180046010.1002/marc.201800460 ↗
12. 10.1016/j.progpolymsci.2015.10.00210.1016/j.progpolymsci.2015.10.002 ↗
13. 10.1002/marc.20130073010.1002/marc.201300730 ↗
14. 10.1039/C7PY01107E10.1039/C7PY01107E ↗
15. 10.1039/C8PY01421C10.1039/C8PY01421C ↗
16. 10.1002/anie.20151115910.1002/anie.201511159 ↗
17. 10.1007/s00396-014-3255-310.1007/s00396-014-3255-3 ↗
18. 10.1021/ma061373910.1021/ma0613739 ↗
19. 10.1021/acsmacrolett.9b0060610.1021/acsmacrolett.9b00606 ↗
20. 10.1039/D1PY00995H10.1039/D1PY00995H ↗
21. 10.1002/marc.20180046710.1002/marc.201800467 ↗
22. 10.1039/C9CC04445K10.1039/C9CC04445K ↗
23. 10.1021/acs.macromol.8b0164510.1021/acs.macromol.8b01645 ↗
24. 10.1002/anie.20191175810.1002/anie.201911758 ↗
25. 10.1016/j.jcis.2022.03.04410.1016/j.jcis.2022.03.044 ↗
26. 10.1021/acs.biomac.6b0178810.1021/acs.biomac.6b01788 ↗
27. 10.1002/marc.20180032510.1002/marc.201800325 ↗
28. 10.1002/marc.20150002810.1002/marc.201500028 ↗
29. 10.1039/D1PY00517K10.1039/D1PY00517K ↗
30. 10.1039/C3PY01306E10.1039/C3PY01306E ↗
31. 10.1002/adtp.20180003010.1002/adtp.201800030 ↗
32. 10.1016/j.drudis.2019.09.00610.1016/j.drudis.2019.09.006 ↗
33. 10.1021/acs.biomac.8b0014510.1021/acs.biomac.8b00145 ↗
34. 10.1016/j.biomaterials.2013.01.08410.1016/j.biomaterials.2013.01.084 ↗
35. 10.1007/s11095-006-0284-810.1007/s11095-006-0284-8 ↗
36. 10.1038/s12276-020-0384-210.1038/s12276-020-0384-2 ↗
37. 10.1186/1477-3163-5-1410.1186/1477-3163-5-14 ↗
38. 10.3109/1071576100366755410.3109/10715761003667554 ↗
39. 10.1038/nrm224010.1038/nrm2240 ↗
40. 10.1039/C7OB01975K10.1039/C7OB01975K ↗
41. Xu X. · Adv. Mater. · 2017 · 29 · 1
42. 10.1021/acsomega.9b0292310.1021/acsomega.9b02923 ↗
43. 10.7150/thno.4539210.7150/thno.45392 ↗
44. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
45. 10.1021/acs.biomac.9b0062810.1021/acs.biomac.9b00628 ↗
46. 10.1021/acs.accounts.9b0013610.1021/acs.accounts.9b00136 ↗
47. 10.1002/macp.20120050210.1002/macp.201200502 ↗
48. 10.1002/marc.20180069910.1002/marc.201800699 ↗
49. 10.1039/C7PY01908D10.1039/C7PY01908D ↗
50. 10.1016/j.jconrel.2017.08.02610.1016/j.jconrel.2017.08.026 ↗
51. 10.1039/D2PY00207H10.1039/D2PY00207H ↗
52. 10.1021/acsbiomaterials.0c0177110.1021/acsbiomaterials.0c01771 ↗
53. 10.1021/acs.biomac.6b0004110.1021/acs.biomac.6b00041 ↗
54. 10.1021/acs.nanolett.6b0163210.1021/acs.nanolett.6b01632 ↗
55. 10.1021/acs.biomac.1c0101010.1021/acs.biomac.1c01010 ↗
56. 10.1021/acs.biomac.9b0010110.1021/acs.biomac.9b00101 ↗
57. 10.1039/D1PY00371B10.1039/D1PY00371B ↗
58. 10.1021/acs.biomac.0c0087910.1021/acs.biomac.0c00879 ↗
59. 10.1021/acs.biomac.1c0103910.1021/acs.biomac.1c01039 ↗
60. 10.1016/j.biomaterials.2020.12057410.1016/j.biomaterials.2020.120574 ↗
61. 10.3390/gels806036110.3390/gels8060361 ↗
62. 10.1039/C5PY00166H10.1039/C5PY00166H ↗
63. 10.3390/pharmaceutics1302020810.3390/pharmaceutics13020208 ↗
64. 10.1039/D1BM01548F10.1039/D1BM01548F ↗
65. Pearce A. K. · Adv. Healthcare Mater. · 2020 · 9 · 110.1002/adhm.202000892 ↗
66. 10.1021/acs.biomac.9b0071310.1021/acs.biomac.9b00713 ↗
67. 10.1002/anie.20210892810.1002/anie.202108928 ↗
68. 10.1021/acsmacrolett.7b0073110.1021/acsmacrolett.7b00731 ↗
69. 10.1021/ja303372u10.1021/ja303372u ↗
70. 10.1038/s41565-021-00858-810.1038/s41565-021-00858-8 ↗
71. 10.1002/smll.20090000510.1002/smll.200900005 ↗
72. 10.1016/j.bpj.2018.11.313410.1016/j.bpj.2018.11.3134 ↗
73. 10.2147/IJN.S20110710.2147/IJN.S201107 ↗
74. 10.1186/s11671-018-2728-610.1186/s11671-018-2728-6 ↗
75. 10.3390/pharmaceutics1204037110.3390/pharmaceutics12040371 ↗
76. 10.1016/j.cell.2004.08.01710.1016/j.cell.2004.08.017 ↗
77. 10.1111/j.1600-0854.2008.00733.x10.1111/j.1600-0854.2008.00733.x ↗